Yasuyuki ISHII, PhD

Co-Founder,Chairman, Member of the Board of Directors

Dr. Ishi has served as President, Chief Executive Officer and Director of REGiMMUNE since June 2014. Dr. Ishii is the team leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology. His research is focused on the development of vaccines for Japanese cedar pollinosis. Previously, as a researcher at Kirin Pharmaceutical Division and the La Jolla Institute for Allergy & Immunology, he studied the regulatory system for IgE antibody responses in the laboratory of Dr. Kimishige Ishizaka, a pioneer in the discovery of the IgE antibody. To explore immunoregulatory systems against allergic reactions, Dr. Ishii moved to the Agency of Industrial Science and Technology in the Ministry of International Trade and Industry, which was reorganized to the National Institute of Advanced Industrial Science and Technology (AIST). Dr. Ishii is also a visiting associate professor in the Division of Immune Regulation at the graduate school of Chiba University. He received his BS, MS and PhD degrees in Chemistry from the Tokyo Institute of Technology and is a member of the American Association of Immunologists, Japanese Society of Immunology and Japanese Society of Allergology.

Kenzo Kosuda

President&CEO/ Member of the Board

Mr. Kosuda joined REGiMMUNE as chief financial officer in 2013. In this role, he is responsible for finance, investor relations, operations, strategy and corporate development. He has over twenty years of extensive experience in financial area throughout his experience at Deloitte Tohmatsu and PwC as professional consultant and his own accounting firm to help emerging companies. Prior to join REGiMMUNE, he served as CFO at Sparx Asset Management where he led the first IPO of an asset management company in Japan.
He has an BA degree in Economics from the Keio University in Japan and is a Chartered Accountant.


Member of the Board of Directors

Prior to joining the board in February 2007, Ms. Clayton retired as President and Chief Executive Officer of Abmaxis, Inc., which was acquired by Merck & Co. As VP and Treasurer at Genentech, Inc., the first biopharmaceutical company, Ms. Clayton was actively involved in the early financing of the biotechnology industry. Prior to her role at Abmaxis, she co-founded Raven Biotechnologies, a cell biology company developing monoclonal antibody products, and served as its President and Chief Financial Officer. During her 25 years as an executive in the life science industry, Ms. Clayton was Chief Financial Officer, President or Chief Executive Officer in several companies including Protein Design Labs, now PDL BioPharma, Inc.; Cygnus, Inc., a drug delivery company; and CBYON, a medical technology company sold to GE Medical Systems. She is a member of the Board and Audit committee of Metro Bancorp and a member of the Board of Metro United Bank and Chairman of its Credit committee. Ms. Clayton received a BS in Chemistry from Smith College and an MBA from the Stanford University Graduate School of Business.

Hiroyuki Misawa, PhD

Member of the Board of Directors
Japan Asia Investment Co., Ltd.

Dr. Misawa is currently one of the directors of investment group in Japan Asia Investment Co., Ltd. (JAIC). With over 10 years' experience in healthcare investment, he leads biotech, medical device and medical service investments in JAIC and is a member of investment committee of a fund of funds in JAIC which invest to top tier Life Science VCs in Europe. He also plays a major role as investment committee member of some JAIC's investment funds in China. Prior to join JAIC group, Dr. Misawa held academic position as an assistant professor at Kurume University and University of Shizuoka, and a visiting research fellow at Baylor College of Medicine for 7 years. He received his BS, MS and PhD degrees in Biochemistry from Saitama University.

Joseph S. McCracken, DVM, MS

Member of the Board of Directors

Joseph McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. Dr. McCracken also serves on the Board of Alkahest, Inc., Genkyotex S.A., Savara Pharmaceuticals and Nexvet Biopharma. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University.

Hiroyuki Tanaka

Audit & Supervisory Board Member

Attorney at Law and TAX,CPA, Managing Partner at Tanaka Law, Accounting and Tax office

Mr.Tanaka graduated School of law of Tokyo University. He joined Deloitte Touche Tohmatsu(DTT) as CPA. He quit DTT and passed The National Bar Examination and started his own Law/Tax/Accountig office.